Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2008 1
2009 5
2010 2
2011 4
2012 4
2013 5
2014 8
2015 8
2016 1
2017 3
2018 7
2019 14
2020 11
2021 12
2022 12
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers.
Kenney RT, Cini JK, Dexter S, DaFonseca M, Bingham J, Kuan I, Chawla SP, Polasek TM, Lickliter J, Ryan PJ. Kenney RT, et al. Among authors: chawla sp. Front Immunol. 2024 Feb 29;15:1362775. doi: 10.3389/fimmu.2024.1362775. eCollection 2024. Front Immunol. 2024. PMID: 38487528 Free PMC article. Clinical Trial.
The Combination of Methioninase and Ethionine Exploits Methionine Addiction to Selectively Eradicate Osteosarcoma Cells and Not Normal Cells and Synergistically Down-regulates the Expression of C-MYC.
Aoki Y, Kubota Y, Han Q, Masaki N, Obara K, Bouvet M, Chawla SP, Tome Y, Nishida K, Hoffman RM. Aoki Y, et al. Among authors: chawla sp. Cancer Genomics Proteomics. 2023 Dec;20(6suppl):679-685. doi: 10.21873/cgp.20415. Cancer Genomics Proteomics. 2023. PMID: 38035708 Free PMC article.
From Mendel to Gene Therapy.
Jeffrey SL, Brigham DA, Chawla SP, Federman N, Hall FL, Gordon EM. Jeffrey SL, et al. Among authors: chawla sp. Anticancer Res. 2023 Oct;43(10):4257-4261. doi: 10.21873/anticanres.16620. Anticancer Res. 2023. PMID: 37772566 No abstract available.
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.
Subbiah V, Chawla SP, Conley AP, Wilky BA, Tolcher A, Lakhani NJ, Berz D, Andrianov V, Crago W, Holcomb M, Hussain A, Veldstra C, Kalabus J, O'Neill B, Senne L, Rowell E, Heidt AB, Willis KM, Eckelman BP. Subbiah V, et al. Among authors: chawla sp. Clin Cancer Res. 2023 Aug 15;29(16):2988-3003. doi: 10.1158/1078-0432.CCR-23-0974. Clin Cancer Res. 2023. PMID: 37265425 Free PMC article. Clinical Trial.
Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311).
Chawla SP, Tellez WA, Chomoyan H, Valencia C, Ahari A, Omelchenko N, Makrievski S, Brigham DA, Chua-Alcala V, Quon D, Moradkhani A, Gordon EM. Chawla SP, et al. Front Oncol. 2023 May 10;13:1116937. doi: 10.3389/fonc.2023.1116937. eCollection 2023. Front Oncol. 2023. PMID: 37234994 Free PMC article.
SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma.
Gordon EM, Chawla SP, Tellez WA, Younesi E, Thomas S, Chua-Alcala VS, Chomoyan H, Valencia C, Brigham DA, Moradkhani A, Quon D, Srikureja A, Wong SG, Tseng W, Federman N. Gordon EM, et al. Among authors: chawla sp. Cancers (Basel). 2023 Jan 31;15(3):906. doi: 10.3390/cancers15030906. Cancers (Basel). 2023. PMID: 36765863 Free PMC article.
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma.
Nguyen J, Takebe N, Kummar S, Razak A, Chawla SP, George S, Patel SR, Keohan ML, Movva S, O'Sullivan Coyne G, Do K, Juwara L, Augustine B, Steinberg SM, Kuhlmann L, Ivy SP, Doroshow JH, Chen AP. Nguyen J, et al. Among authors: chawla sp. Clin Cancer Res. 2023 Apr 3;29(7):1200-1208. doi: 10.1158/1078-0432.CCR-22-2145. Clin Cancer Res. 2023. PMID: 36302173 Free PMC article.
A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations.
Rodón J, Funchain P, Laetsch TW, Arkenau HT, Hervieu A, Singer CF, Murciano-Goroff YR, Chawla SP, Anthony K, Yamamiya I, Liu M, Halim AB, Benhadji KA, Takahashi O, Delaloge S. Rodón J, et al. Among authors: chawla sp. Future Oncol. 2022 Sep;18(30):3377-3387. doi: 10.2217/fon-2022-0305. Epub 2022 Aug 30. Future Oncol. 2022. PMID: 36039910 Free PMC article.
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results.
Attia S, Bolejack V, Ganjoo KN, George S, Agulnik M, Rushing D, Loggers ET, Livingston MB, Wright J, Chawla SP, Okuno SH, Reinke DK, Riedel RF, Davis LE, Ryan CW, Maki RG. Attia S, et al. Among authors: chawla sp. Cancer Med. 2023 Jan;12(2):1532-1539. doi: 10.1002/cam4.5044. Epub 2022 Aug 10. Cancer Med. 2023. PMID: 35950293 Free PMC article. Clinical Trial.
97 results